A prospective, observational safety study of patients with BRAFV600‐mutated unresectable or metastatic melanoma treated with vemurafenib [Zelboraf Safety Study (ZeSS)]

Abstract

Vemurafenib is approved in more than 90 countries for the treatment of patients with BRAF ^V600‐mutated metastatic melanoma.^1,2 In the pivotal BRIM‐3 trial, treatment‐emergent cutaneous side effects were associated with vemurafenib, including the development of epithelial tumours and, in rare cases, new primary melanomas.^3,4 QTc interval prolongation and hepatic laboratory abnormalities were also noted.^3,4

This article is protected by copyright. All rights reserved.

https://ift.tt/2re3jrs